The Use of Adaptive Proximal Scaphoid Implant (APSI): Long Term Follow-up
Launched by AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA · Jan 29, 2025
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients who underwent APSI implant surgery in the period from December 1999 to December 2016, with surgery performed via dorsal or volar approach in the case of previous surgical access;
- • collection of informed consent to the processing of personal data by the Patients contacted in order to be included in the study.
- Exclusion Criteria:
- • patients for whom it was not possible to obtain informed consent to the processing of personal data.
About Azienda Ospedaliera Universitaria Integrata Verona
Azienda Ospedaliera Universitaria Integrata Verona is a leading academic hospital institution in Italy, dedicated to advancing healthcare through innovative clinical research and patient care. With a strong emphasis on collaboration between its medical staff and academic partners, the institution integrates comprehensive clinical services with cutting-edge research initiatives. This multidisciplinary approach ensures the delivery of high-quality healthcare while contributing to the development of new medical knowledge and therapies. The organization is committed to improving patient outcomes and fostering evidence-based practices in the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported